Literature DB >> 11872515

Annual cost of bipolar disorder to UK society.

Roben Das Gupta1, Julian F Guest.   

Abstract

BACKGROUND: The socio-economic impact of bipolar disorder in the UK is unknown. AIMS: To estimate the annual socio-economic burden imposed by bipolar disorder on UK society.
METHOD: The annual cost of resource use attributable to managing bipolar disorder was calculated. Indirect societal costs were also calculated.
RESULTS: The annual National Health Service (NHS) cost of managing bipolar disorder was estimated to be 199 million pounds sterling , of which hospital admissions accounted for 35%. The annual direct non-health-care cost was estimated to be 86 million pounds sterling annually and the indirect societal cost was estimated to be 1770 million pounds sterling annually.
CONCLUSIONS: The annual cost to UK society attributable to bipolar disorder was estimated to be 2 billion pounds sterling at 1999/2000 prices (estimated 297 000 people with the disorder). Ten per cent of this cost is attributable to NHS resource use, 4% to non-health-care resource use and 86% to indirect costs.

Entities:  

Mesh:

Year:  2002        PMID: 11872515     DOI: 10.1192/bjp.180.3.227

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  37 in total

1.  [Annual costs of bipolar disorders in Germany].

Authors:  C Runge; H Grunze
Journal:  Nervenarzt       Date:  2004-09       Impact factor: 1.214

2.  Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode.

Authors:  Mattias Ekman; Peter Lindgren; Carolin Miltenburger; Genevieve Meier; Julie C Locklear; Mary Lou Chatterton
Journal:  Pharmacoeconomics       Date:  2012-06-01       Impact factor: 4.981

3.  Measuring health-related quality of life in bipolar disorder: relationship of the EuroQol (EQ-5D) to condition-specific measures.

Authors:  Hazel Hayhurst; Stephen Palmer; Rosemary Abbott; Tony Johnson; Jan Scott
Journal:  Qual Life Res       Date:  2006-09-14       Impact factor: 4.147

4.  Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers.

Authors:  Ronald C Kessler; Hagop S Akiskal; Minnie Ames; Howard Birnbaum; Paul Greenberg; Robert M A Hirschfeld; Robert Jin; Kathleen R Merikangas; Gregory E Simon; Philip S Wang
Journal:  Am J Psychiatry       Date:  2006-09       Impact factor: 18.112

Review 5.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

6.  Introduction. Animal models of neuropsychiatric disorders.

Authors:  Melinda A Novak; Jerrold S Meyer
Journal:  ILAR J       Date:  2014

Review 7.  Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature.

Authors:  Ralph P Insinga; Erik J Dasbach; Elamin H Elbasha
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

8.  Pattern of healthcare resource utilization and direct costs associated with manic episodes in Spain.

Authors:  Monica Tafalla; Luis Salvador-Carulla; Jerónimo Saiz-Ruiz; Teresa Diez; Luis Cordero
Journal:  BMC Psychiatry       Date:  2010-04-28       Impact factor: 3.630

9.  The mood stabiliser lithium suppresses PIP3 signalling in Dictyostelium and human cells.

Authors:  Jason S King; Regina Teo; Jonathan Ryves; Jonathan V Reddy; Owen Peters; Ben Orabi; Oliver Hoeller; Robin S B Williams; Adrian J Harwood
Journal:  Dis Model Mech       Date:  2009-04-21       Impact factor: 5.758

10.  A systematic review of the evidence of the burden of bipolar disorder in Europe.

Authors:  Liberty Fajutrao; Julie Locklear; Jennifer Priaulx; Anne Heyes
Journal:  Clin Pract Epidemiol Ment Health       Date:  2009-01-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.